The ERK pathway has been shown to drive the selection of resistant clones during induction therapy for AML in vitro and elevated ERK1/2 activity has also been observed in AML patients who have developed resistance to FLT3-targeted inhibitors27,28. The gene discussed is MAPK3; the disease is acute myeloid leukemia.